Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

YYM BioSciences prices underwritten public offering of 25,000,000 common shares

YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today announced that it has priced an underwritten public offering of 25,000,000 common shares at a price to the public of $1.60 per share.

15 Dec 2010

Abbott initiates ABT-806 Phase 1 trial in EGFR expressing tumors

Life Science Pharmaceuticals (LSP) announced today a milestone related to monoclonal-antibody (mAb) 806 licensed to Abbott. A Phase 1 trial with ABT-806, a humanized version of mAb 806 that selectively targets the epidermal growth factor receptor (EGFR), has been initiated by Abbott in the U.S. The trial will assess the safety and pharmacokinetics of ABT-806 in patients with advanced solid tumors likely or known to express EGFR.

15 Dec 2010

MVI, Merck and NYU collaborate to research potential malaria vaccine

Development of a vaccine to prevent the malaria parasite from entering the human liver is the goal of a new collaboration announced today by global leaders in malaria research and vaccine development. The PATH Malaria Vaccine Initiative (MVI), Merck (known outside the US and Canada as MSD), and NYU Langone Medical Center are working together to evaluate an approach targeting a novel part of a major surface protein on the malaria parasite. Malaria is estimated to kill close to 900,000 people each year with the majority of deaths occurring in children under the age of five in sub-Saharan Africa.

14 Dec 2010

Glycotope receives innovation award 2010 for GlycoExpress technology platform

Glycotope GmbH, a leading glycobiology company, has won the innovation award 2010 jointly presented by the German states of Berlin and Brandenburg in recognition of the company's GlycoExpress™ technology platform. GlycoExpress™ combines a very efficient improvement of the activities and side effects of a broad range of protein biopharmaceuticals with the suitability for a much broader patient population and a very high productivity.

14 Dec 2010

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.

14 Dec 2010

New collaboration to develop vaccine to prevent malaria parasite from entering human liver

14 Dec 2010

Clinical trail shows 2009 H1N1 influenza vaccine safe and effective in asthma patients

Results from a government-sponsored clinical trial of inactivated 2009 H1N1 influenza vaccine in people with asthma indicate that a single dose of vaccine was safe and induced a strong immune response predictive of protection.

14 Dec 2010

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Immunomedics Inc. and UCB today announced the enrollment of the first patient into EMBODY™ 1, one of two pivotal Phase III studies of epratuzumab in patients with moderate to severe systemic lupus erythematosus (SLE). Patient enrollment for EMBODY™ 2 has also begun.

14 Dec 2010

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

Intercell AG announced today preliminary clinical results on its investigational Travelers' Diarrhea (TD) Vaccine Patch program and the decision not to pursue further the development of this vaccine candidate. The decision was made following the receipt of results of its randomized and placebo-controlled Phase III study (ELT301) with 2036 travelers from Europe to Mexico and Guatemala as well as the pilot efficacy Phase II trial (ELT209) with 723 travelers from Europe to India.

13 Dec 2010

TRL, Anaphore partner to develop novel protein therapies for autoimmune diseases

Tanabe Research Laboratories U.S.A. Inc., (TRL) announced today that it has entered into a partnership with Anaphore Inc. for the research and preclinical development of novel protein therapies for autoimmune diseases based on Anaphore's proprietary Atrimer™ technology.

13 Dec 2010

Pain Therapeutics completes special, one-time nondividend cash distribution

Pain Therapeutics, Inc. announced today the completion of a special, one-time nondividend cash distribution of $2.00 per share, or an aggregate of about $86 million. In connection with this event, Nasdaq® will adjust the price of PTIE by $2.00 per share at today's open.

13 Dec 2010

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.

13 Dec 2010

OraSure commences enrollment in final study for FDA approval of OraQuick Rapid HIV-1/2 OTC test

OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that it has enrolled the first subject in its final phase of clinical studies for United States Food and Drug Administration ("FDA") approval of the Company's OraQuick® Rapid HIV-1/2 test for sale in the U.S. consumer or over-the-counter ("OTC") market.

13 Dec 2010

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preliminary results from an ongoing Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol®), a standard chemotherapy regimen, in patients with metastatic breast cancer.

10 Dec 2010

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

10 Dec 2010

GeoVax's phase 2a trial results indicate excellent safety profile for HIV vaccine

GeoVax Labs, Inc., announced today that early results from part A of an ongoing phase 2a clinical trial indicate an excellent safety profile and highly reproducible immunogenicity.

10 Dec 2010

Blocking growth of blood vessels with antibodies could improve treatment of cancerous tumors

A novel strategy of blocking the growth of blood vessels with antibodies should result in improved treatment of cancerous tumors.

10 Dec 2010

Geisinger Medical Center performs first transcervical thymectomy

The Department of Thoracic Surgery at Geisinger Medical Center (GMC) recently performed its first transcervical thymectomy, joining other major academic medical centers nationwide that perform the minimally invasive surgical procedure.

9 Dec 2010

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

Alder Biopharmaceuticals Inc. today announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal of anemia in patients with advanced non-small cell lung cancer.

9 Dec 2010

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease and reported on their application of these criteria in clinical trials during the recently completed National Hemophilia Foundation Annual Meeting.

9 Dec 2010

Antibody News and Research

Further Reading

YYM BioSciences prices underwritten public offering of 25,000,000 common shares

Abbott initiates ABT-806 Phase 1 trial in EGFR expressing tumors

MVI, Merck and NYU collaborate to research potential malaria vaccine

Glycotope receives innovation award 2010 for GlycoExpress technology platform

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

New collaboration to develop vaccine to prevent malaria parasite from entering human liver

Clinical trail shows 2009 H1N1 influenza vaccine safe and effective in asthma patients

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

TRL, Anaphore partner to develop novel protein therapies for autoimmune diseases

Pain Therapeutics completes special, one-time nondividend cash distribution

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

OraSure commences enrollment in final study for FDA approval of OraQuick Rapid HIV-1/2 OTC test

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

GeoVax's phase 2a trial results indicate excellent safety profile for HIV vaccine

Blocking growth of blood vessels with antibodies could improve treatment of cancerous tumors

Geisinger Medical Center performs first transcervical thymectomy

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

Immunology eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News